Folate receptor alpha (FRA) expression in breast cancer: Identification of a new molecular subtype and association with triple negative disease

SpringerPlus

Volumn 1, Issue 1, 2012, Pages 1-9

  O'Shannessy, Daniel J ^a   Somers, Elizabeth B ^a   Maltzman, Julia ^a   Smale, Robert ^b   Fu, Yao Shi ^c  

^a Morphotek Inc   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

^c QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

Breast cancer; Folate receptor alpha; FRA; IHC; Immunohistochemistry; Triple negative breast cancer

Indexed keywords

EID: 84873514477     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-1-22     Document Type: Article

References (31)

1. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer 109:1721-1728
2. Bueno R, Appasani K, Mercer H, Lester S, Sugarbaker D (2001) The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 121(2):225-233
3. Dosio F, Milla P, Cattel L (2010) EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs 11(12):1424-1433
4. Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, Phillips MD, Nicolaides NC, Sass PM, Grasso L (2007) Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 7:6
5. Elnakat H, Ratnam M (2004) Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 56(8):1067-1084
6. Elnakat H, Gonit M, Salazar MD, Zhang J, Basrur V, Gunning W, Kamen B, Ratnam M (2009) Regulation of folate receptor internalization by protein kinase C alpha. Biochemistry 48(34):8249-8260
7. Franklin WA, Waintrub M, Edwards D, Christensen K, Prendegrast P, Woods J, Bunn PA, Kolhouse JF (1994) New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer Suppl 8:89-95
8. Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S (2012) Targeting triple negative breast cancer: optimising therapeutic outcomes. Ann Oncology, Epub ahead of print
9. Hartmann LC, Keeney GL, Lingle WL, Christianson TJ, Varghese B, Hillman D, Oberg AL, Low PS (2007) Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 121(5):938-942
10. Iwakiri S, Sonobe M, Nagai S, Hirata T, Wada H, Miyahara R (2008) Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Ann Surg Oncol 15(3):889-899
11. Kelemen LE (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119(2):243-250
12. Kelley KM, Rowan BG, Ratnam M (2003) Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer Res 63(11):2820-2828
13. Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Vander Els N, Phillips MD, Schweizer C, Weil SC, Larson SM, Old LJ (2010) Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 16(21):5288-5295. doi:10.1158/1078-0432.CCR-10-0700
14. Low PS, Kularatne SA (2009) Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 13(3):256-262. doi:10.1016/j.cbpa.2009.03.022
15. Luhrs C, Raskin CA, Durbin R, Wu B, Sadasivan E, Rothenberg SP (1992) Transfection of a glycosylated phosphatidylinositol-anchored folate-binding protein complementary DNA provides cells with the ability to survive in low folate medium. J Clin Invest 90(3):840-847
16. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M (2012) Dissecting the heterogeneity of triple negative breast cancer. J Clin Oncol 30(15):1879-1887
17. O'Shannessy DJ, Somers EB, Albone E, Cheng X, Park YC, Tomkowicz BE, Hamuro Y, Kohl TO, Forsyth TM, Smale R, Fu Y-S, Nicolaides NC (2011) Characterization of the human folate receptor alpha via novel antibodybased probes. Oncotarget 2(12):1227-1243
18. O'Shannessy DJ, Yu G, Smale R, Fu Y-S, Singhal S, Thiel RP, Somers EB, Vachani A (2012) Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance Oncotarget 3(4):414-425
19. O'Shaughnessy J, Schwartzberg LS, Danso MA et al (2011) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer. J Clin Oncol 29, Supplement 15 s): Abstract 1007
20. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338(2):284-293
21. Rochman H, Selhub J, Karrison T (1985) Folate binding protein and the estrogen receptor in breast cancer. Cancer Detect Prev 8(1-2):71-75
22. Ross JF, Chaudhuri PK, Ratnam M (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73(9):2432-2443
23. Shia J, Klimstra DS, Nitzkorski JR, Low PS, Gonen M, Landmann R, Weiser MR, Franklin WA, Prendergast FG, Murphy L, Tang LH, Temple L, Guillem JG, Wong WD, Paty PB (2008) Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol 39(4):498-505
24. Siegel R, Naishadham D (2012) Jemal A (2012) Cancer statistics, CA Cancer. J Clin 62:10-29
25. Spannuth WA, Sood AK, Coleman RL (2010) Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 10(3):431-437. doi:10.1517/14712591003592069
26. Stein R, Goldenberg DM, Mattes MJ (1991) Normal tissue reactivity of four antitumor monoclonal antibodies of clinical interest. Int J Cancer 47(2):163-169. doi:10.1002/ijc.2910470202
27. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M (1997) Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74(2):193-198
28. Toffoli G, Russo A, Gallo A, Cernigoi C, Miotti S, Sorio R, Tumolo S, Boiocchi M (1998) Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 79(2):121-126
29. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR, Kamen BA (1992a) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52(12):3396-3401
30. Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA (1992b) Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res 52(23):6708-6711
31. Wu M, Gunning W, Ratnam M (1999) Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 8(9):775-782